SecBot SecBot

MTNB

Matinas BioPharma Holdings, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001582554 Biotech & Drug Discovery
$1.66 −0.04 (−2.41%)
Oct 26 4:00 PM ET · prev $1.70
Market cap
$1.7M
Nano cap
Next earnings
Nov 9
in 14 days
1 year
+8.4%
from $1.53 · Oct 27
30 days
−34.4%
from $2.53
52-week range
$0.1600–4.47
−63% from high · low Sep 18
Avg volume 20D
139.8K
Sep 29 spike 757.5K
Short interest
56.2K
≈5.7% of shares · −87.3%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 3 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/5 ·Next Earnings date, Nov 9, 2026
Strongest BEARISH Matinas BioPharma received a third NYSE American non-compliance notice, this time for failing Section…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • Short sellersCOVERING

    Short interest −87.3% to 56.2K shares. 1.0 days to cover, ≈5.7% of shares.

  • TrendUPTREND

    28% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCDOUBLED71,040$43.5K
CITADEL ADVISORS LLCTRIM15,465$9.5K
MORGAN STANLEYTRIM344$172.00
UBS Group AGTRIM184$92.00
Farther Finance Advisors, LLCNEAR_EXIT5$3.00
UBS Group AGDOUBLED607$356.00
OSAIC HOLDINGS, INC.NEAR_EXIT50$28.00
MORGAN STANLEYDOUBLED561$1.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Oct 2024
Recent actions
DateFirmActionRating
Oct 31, 2024Maxim Group
DOWNGRADE
DOWNGRADEHold
Jan 31, 2023HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 13, 2020Aegis Capital
MAINTAIN
MAINTAINBuy
Jan 27, 2020Piper Sandler
INITIATE
INITIATEOverweight
Jan 24, 2020SunTrust Robinson Humphrey
INITIATE
INITIATEBuy
Jun 26, 2019HC Wainwright & Co.
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 10, 2026
STERN ADAM K
10%+ Owner
OTHER$49.5K
Jul 10, 2026
STERN ADAM K
10%+ Owner
AWARD$120.6K
Jul 10, 2026
STERN ADAM K
10%+ Owner
EXERCISE$120.6K
Jul 10, 2026
STERN ADAM K
10%+ Owner
AWARD$220.6K
Jul 10, 2026
STERN ADAM K
10%+ Owner
EXERCISE$220.6K
Jul 10, 2026
STERN ADAM K
10%+ Owner
EXERCISE$220.6K
Jul 10, 2026
STERN ADAM K
10%+ Owner
EXERCISE$120.6K
Jun 10, 2026
Sanitam Partners LLC
10%+ Owner
OTHER$823.92

Earnings setup

Estimates
Nov 9
reports in 14 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
56,158
shares short
-87.3%
vs prior settlement
1.0
days to cover
≈5.7%
of shares outstanding
Trading halts
Jul 13, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 SEC
Matinas BioPharma filed a Certificate of Amendment to effect a 1-for-15 reverse stock split, effective September 28…
8-K — Impact 4/10
Sep 16, 2026 SEC
Matinas BioPharma announced a 1-for-15 reverse stock split, effective September 28, 2026, to regain compliance with…
8-K — Impact 4/10
Sep 4, 2026 SEC
Matinas BioPharma received a third NYSE American non-compliance notice, this time for failing Section 1003(a)(i)…
8-K — Impact 7/10
Sep 4, 2026 Other
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”
Jul 10, 2026 Insider
STERN ADAM K acquired 141,462 shares
10%+ Owner @ $0.3500 ($49.5K)
Jul 10, 2026 Insider
STERN ADAM K was granted 344,710 shares
10%+ Owner @ $0.3500 ($120.6K)
Jul 10, 2026 Insider
STERN ADAM K acquired via exercise 344,710 shares
10%+ Owner @ $0.3500 ($120.6K)
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
71,040 shares ($43.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
MTNB Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Sep 4, 2026
Press release
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BEDMINSTER, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on…
Aug 12, 2026
Earnings date
MTNB Q2 2026 Earnings Scheduled — 2026-08-12
Jul 13, 2026
Trading halt
Halt Resumed: MTNB — trading resumed after T3 (News and Resumption Times)
Halted 2026-07-13T11:34:26.000Z | Resumed 2026-07-13T12:20:00.000Z
Jul 13, 2026
M&A
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial…
Jul 13, 2026
Trading halt
Trading Halt: MTNB — T1 (News Pending)
Matinas BioPharma Holdings, Inc. | Market: AMEX | Code: T1 — News Pending

SecBot reports

9 filings · 0 bullish · 7 bearish · 2 neutral
All MTNB filing & press-release reports (9)